RA CAPITAL MANAGEMENT, L.P.

Position in AVTX — Avalo Therapeutics, Inc.

CIK 1346824 BOSTON, MA

Position in AVTX

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$18,480,000

+$8,581,888 QoQ

Shares Held

1,000,000

+50.8% QoQ

Ownership

1.86%

of shares outstanding

% of Portfolio

0.16%

of 13F equity value

Holder Rank

#24

of 126 holders

Holding Since

Sep 2024

8 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

RA CAPITAL MANAGEMENT, L.P. holds $11,082,969,028 across 75 Biotechnology names. AVTX ranks #61 (0.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	10,281,496	$2,742,280,613
2	PBLS	Parabilis Medicines, Inc.	28,933,371	$791,906,364
3	RYTM	Rhythm Pharmaceuticals, Inc.	6,666,837	$740,218,912
4	PCVX	Vaxcyte, Inc.	11,474,599	$667,018,439
5	SION	Sionna Therapeutics, Inc.	9,905,045	$435,722,929
6	TYRA	Tyra Biosciences, Inc.	12,198,625	$389,624,082
7	EWTX	Edgewise Therapeutics, Inc.	8,392,730	$340,996,619
8	NAMS	NewAmsterdam Pharma Co N.V.	9,883,524	$330,779,298

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$18,480,000	1,000,000	+50.8%	Shares	Sole	2026-08-14
2026-06-30	$64,367,669	3,483,099	—	Shares	Sole	2026-08-14
2026-03-31	$9,898,112	662,968	0.0%	Shares	Sole	2026-05-15
2025-12-31	$12,039,498	662,968	0.0%	Shares	Sole	2026-02-17
2025-09-30	$8,426,323	662,968	-28.9%	Shares	Sole	2025-11-14
2025-06-30	$4,655,535	932,973	-3.5%	Shares	Sole	2025-08-14
2025-03-31	$7,745,670	967,000	0.0%	Shares	Sole	2025-05-15
2024-12-31	$7,184,810	967,000	0.0%	Shares	Sole	2025-02-14
2024-09-30	$9,186,500	967,000	—	Shares	Sole	2024-11-14
No filing history on record for this holder in this stock.